You meant ADT. Two months is typical. the neoadjuvant ADT is thought to radio-sensitize the cancer. What they usually like to see is the PSA drop to undetectable before starting the radiation. That indicates that the cancer cells have been "crippled" to the point that they are no longer active and releasing PSA. In this inactive state, the cells are not capable of using DNA-repair to recover from the radiation injury.
Much of our knowledge about
it comes from its use along with
primary radiation. An early randomized trial proved that 2 months neoadjuvant (added before radiation begins) + 2 months concurrent ADT significantly improved oncological outcomes, especially in intermediate risk men:
www.nejm.org/doi/full/10.1056/NEJMoa1012348The benefit was maintained even at higher radiation doses:
www.redjournal.org/article/S0360-3016(12)03331-7/fulltextOne study suggested that an extended course 6 months of neoadjuvant ADT before primary RT had better results:
/www.ncbi.nlm.nih.gov/pubmed/23618502But a randomized trial (RTOG 9910) proved that 3 months neoadjuvant gave equivalent oncological results with less toxicity.
www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70063-8/abstractPSA response during neoadjuvant ADT is the most significant prognostic factor.
Most of the protocols with salvage radiation have followed what had been learned from primary radiation. In fact, I've never seen an SRT clinical trial that did not include 2-3 months of neoadjuvant ADT. There's been much less study on the timing and duration of adjuvant ADT given with SRT. We finally learned from an RCT (GETUG AFU-15) that adjuvant ADT improved survival when used with SRT. There is an RCT running (RADICALS) that will provide more info on optimum duration:
/pcnrv.blogspot.com/2016/08/combining-androgen-deprivation-therapy.htmlIf your RO can provide the European study showing that a shorter neoadjuvant ADT period is sufficient with SRT, I would love to read it.